Soluble ST2 biomarker and reverse remodelling in patients with systolic heart failure

摘要

Left ventricular reverse remodelling (LVRR) has generally been suggested as an important alteration potentially predicting favorable prognosis in patients with systolic heart failure. By definition, it is a stepwise and time-dependent improvement in systolic functions characterized by a left ventricular ejection fraction (LVEF) increase of >15% or a LVEF increase of >10% along with a significant decline in end-systolic diameter or volume index during 1 year follow-up. Importantly, certain novel biomarkers including soluble ST2 (sST2) were suggested to have an independent association with LVRR.